If true, it seems like van der Horst would be a good addition to the team with his experience/knowledge in the cancer/oncology field. Here is a GTCBio profile on him that I found online.

"Edward van der Horst has an in-depth knowledge of oncology and cancer-associated signal transduction and over 15 years of experience in both biotechnology and drug development. He received his Ph.D. in Biochemistry at the Max-Planck-Institute for Biochemistry, Germany under Dr. Axel Ullrich. Edward’s discoveries contributed to the founding of U3Pharma AG/Daiichi-Sankyo, which led to one innovative biologic (U3-1287/AMG-888), currently in a Phase 2 study in non-small cell lung cancer. He completed his postdoctoral fellowship at TULARIK/AMGEN Inc. prior to joining OncoMed Pharmaceuticals, Inc. in 2006, where he developed new anti-cancer antibodies, leading to two IND filings, both of which are currently being evaluated in various solid tumor indications in clinical trials. Since joining Igenica Biotherapeutics in 2010, Edward has successfully led the IGN523 project from its inception to its IND filing and FDA clearance."